Latest news with #SanaBiotechnology
Yahoo
12-07-2025
- Business
- Yahoo
Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley
Sana Biotechnology, Inc. (NASDAQ:SANA) is among the . Morgan Stanley has assumed coverage on Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and a price target of $12.00. This optimism is totally in line with market sentiments that acknowledge the platform's potential to develop tailored therapies driven by engineered cells. The research firm's confidence underpins the recent 12-week and 6-month T1D data for what the firm calls an 'early proof point that helps validate the platform.' This means that the current price is nothing when the scale of opportunities of the company's hypoimmune platform is considered. The analysts believe that the risk/reward profile is closely tied to the upside ahead of sustained pipeline progress. While the risk may be high, the reward is even higher. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The year-to-date returns of 93% delivered by Sana Biotechnology, Inc. (NASDAQ:SANA) is a testament to the company's efforts, particularly in the context of Type 1 Diabetes – a market with the potential to reach as high as $24.36 billion by 2031. Sana Biotechnology, Inc. (NASDAQ:SANA) is a Washington-based biotechnology company that uses engineered cells as medicines across the United States. The core offerings of the company include UP421, SC451, SC291, and SG299. Founded in 2018, the company has agreements with Beam Therapeutics Inc. and Harvard College. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting
Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data from its diabetes therapy program. Pixabay/Public Domain The biotechnology company attended the American Diabetes Association meeting and presented new results from its UP421 cadaveric pancreatic islet cell program. The findings showed that people with Type 1 diabetes can still safely and well tolerate islet cells. At the 24-week milestone, the findings indicated that the transplanted cells were still alive and generating insulin without the need for immunosuppression, according to Citizens JMP. This was verified by MRI imaging, mixed-meal tolerance testing, and baseline C-peptide levels. Sana Biotechnology, Inc. (NASDAQ:SANA) is a Seattle, Washington-based company that specializes in developing treatments for complex diseases like diabetes, cancer, and nervous system disorders. The company's potential for success is largely influenced by its R&D pipeline. Back in 2021, the company inked a deal with Beam Therapeutics for the non-exclusive commercial rights to the biotech's CRISPR-Cas12b gene editing system. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
30-06-2025
- Business
- Yahoo
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 10 best healthcare penny stocks to buy according to analysts. The company's stock surged 12.1% on June 23 after it announced positive six-month follow-up results from an investigator-sponsored, first-in-human study of its type 1 diabetes treatment. A laboratory cultivating cells for the development of gene and cell therapies. The therapy in focus is UP421, which consists of cadaver-sourced pancreatic islet cells that have been genetically modified using Sana's hypoimmune (HIP) technology to evade immune detection. A significant finding is that the transplanted cells were safe, well-tolerated, survived, and continued to produce insulin in the patient without the need for immunosuppressive medicines. The study identified no safety issues, and the HIP-modified islet cells successfully evaded immune responses (both allogeneic and autoimmune). Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician, and Professor at the Clinic for Uppsala University Hospital, stated that the consistent results at four-week, 12-week, and now six-month follow-ups continue to suggest that a functional cure for type 1 diabetes without immunosuppression is possible. Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company. It develops engineered cell therapies to treat serious diseases, aiming to repair or replace damaged cells. Its platforms include hypoimmune cells, gene delivery, and in vivo cell engineering. Sana's pipeline targets conditions like cancer, type 1 diabetes, and genetic disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Yahoo
29-06-2025
- Business
- Yahoo
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 10 best healthcare penny stocks to buy according to analysts. The company's stock surged 12.1% on June 23 after it announced positive six-month follow-up results from an investigator-sponsored, first-in-human study of its type 1 diabetes treatment. A laboratory cultivating cells for the development of gene and cell therapies. The therapy in focus is UP421, which consists of cadaver-sourced pancreatic islet cells that have been genetically modified using Sana's hypoimmune (HIP) technology to evade immune detection. A significant finding is that the transplanted cells were safe, well-tolerated, survived, and continued to produce insulin in the patient without the need for immunosuppressive medicines. The study identified no safety issues, and the HIP-modified islet cells successfully evaded immune responses (both allogeneic and autoimmune). Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician, and Professor at the Clinic for Uppsala University Hospital, stated that the consistent results at four-week, 12-week, and now six-month follow-ups continue to suggest that a functional cure for type 1 diabetes without immunosuppression is possible. Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company. It develops engineered cell therapies to treat serious diseases, aiming to repair or replace damaged cells. Its platforms include hypoimmune cells, gene delivery, and in vivo cell engineering. Sana's pipeline targets conditions like cancer, type 1 diabetes, and genetic disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
BofA Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 14, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) and set a price target of $6.00. The rating update came after the company announced on May 12 plans to present at the BofA Securities 2025 Healthcare Conference. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. In addition, Sana Biotechnology, Inc. (NASDAQ:SANA) presented positive 4- and 12-week clinical results for its ongoing type 1 diabetes study. The company plans to file Investigational New Drug applications (INDs) for SG299 in B-cell-related diseases and for SC451 in type 1 diabetes as early as 2026. As of fiscal Q1 2025, Sana Biotechnology, Inc. (NASDAQ:SANA) has a cash position of $104.7 million, with an expected cash runway into 2026. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineering cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
